Noven Announces Annual Meeting Results

-- Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) today announced the results of its 2004 Annual Meeting of Shareholders. At the meeting, held May 18, 2004, shareholders elected the following persons to the Noven Board of Directors:

  • Sidney Braginsky – President & CEO, Atropos Technology Inc.;
  • John G. Clarkson, M.D. – Professor & Senior Vice President for Medical Affairs & Dean, University of Miami School of Medicine;
  • Donald A. Denkhaus – Chairman, TM Systems, LLC;
  • Robert G. Savage – Worldwide Chairman, Pharmaceutical Group, Johnson & Johnson (Retired);
  • Robert C. Strauss – President, CEO & Chairman, Noven Pharmaceuticals; and
  • Wayne P. Yetter – Advisory Board Chairman, Alterity Partners.

Stockholders also ratified the appointment of Deloitte & Touche LLP Stockholders Stockholders also ratified the appointment of Deloitte & Touche LLP as Shareholders also approved amendments to Noven’s 1999 Long-Term Incentive Plan, and ratified the appointment of Deloitte & Touche LLP as Noven’s independent auditors for 2004. At the meeting, Robert Strauss made a presentation regarding Noven’s business and prospects, a replay of which is available at www.noven.com.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. See www.noven.com for additional information.

Contact:
Investor & Media Contact

Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916